What happened with EDIT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Editas Medicine is developing treatments that edit genes directly inside the body. Its lead candidate, EDIT-401, targets cardiovascular disease and remains in preclinical development. The company plans to concentrate resources on advancing it to demonstrate an effect in humans. It has no approved medicines and has never earned revenue from product sales.
Its revenue comes mainly from drugmakers paying for access to its gene-editing technology and research programs. Bristol Myers Squibb (BMS), its largest revenue source, pays to select and license programs and when development milestones are met; successful products could also generate royalties. Vertex licenses its Cas9 technology for medicines including CASGEVY, which uses cells edited outside the body to treat sickle cell disease and transfusion-dependent beta thalassemia. Editas sold DRI rights to much of the future Vertex fee stream for upfront cash, retaining only specified portions and amounts owed to its licensors.
The business relies on foundational patent rights licensed from Broad Institute and Harvard, which receive a share of relevant Vertex payments. Keeping key licenses requires development efforts and meeting milestones; missed obligations can cost Editas those rights. Its BMS agreement also restricts work or licensing involving certain T cells. With no medicine sales, Editas relies on external financing as well as partner payments to fund development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
CRISPR Therapeutics competes with Editas in gene-edited medicines for cardiovascular disease and inherited blood disorders, but its CASGEVY also uses technology that Vertex pays Editas to license. Watch CASGEVY sales: Editas's Vertex license fees include certain sales-based increases.
Beam Therapeutics competes with Editas on gene-editing treatments for inherited blood disorders while also licensing Editas-controlled patents under an agreement requiring royalties. Beam has no product-sales revenue yet, so its treatment-development progress matters more to this tie than its current revenue from licenses and collaborations.
Intellia Therapeutics's late-stage trials test editing genes directly inside the body using lipid nanoparticles to carry the treatment, an approach Editas is also developing. Results from its Phase 3 lonvo-z and nex-z programs provide a clinical reference for Editas's in vivo pipeline, though they treat different diseases.
Scribe Therapeutics competes with Editas on genetic medicines delivered directly into the body to lower cardiovascular risk, and both pursue inherited blood-disorder treatments. Watch Scribe's programs targeting LDL cholesterol, Lp(a) and triglycerides as Editas concentrates resources on EDIT-401; Scribe currently receives collaboration payments rather than product-sales revenue.
Bristol-Myers Squibb pays Editas for rights to engineered T-cell research programs, making its program selections and development milestones a substantial source of Editas revenue. Editas recognized $23.2 million from this collaboration in 2025, but no longer receives research funding support; option-package deliveries and milestone payments drive the timing of revenue.
Vertex pays Editas to use Cas9 gene-editing patents in CASGEVY, while that medicine treats sickle cell disease and transfusion-dependent beta thalassemia, both targets of Editas's research. Watch CASGEVY sales for potential increases in license fees through 2034, but Editas must pass a portion of the payments to Broad and Harvard.
Prime Medicine shares two important paths with Editas: developing editing treatments that work inside the body and getting paid by BMS for technology used to engineer T-cell medicines. Its liver-disease programs provide an in vivo development reference, while progress under its BMS agreement shows pharmaceutical demand for editing technology used in T cells.
Metagenomi Therapeutics's cardiometabolic editing programs overlap with Editas's cardiovascular focus, with Ionis paying Metagenomi for their collaboration. Watch the partnered programs that switch off genes to reduce protein levels: all four initial targets were still in lead optimization in 2025.
Precision BioSciences offers a different technological yardstick for Editas's medicines that edit genes inside the body: its ARCUS editor works without the guide RNA required by CRISPR. Watch results from its lead PBGENE-HBV and PBGENE-DMD programs to compare clinical progress across the two approaches.
Immatics pays to use Editas's gene-editing technology in gamma-delta T-cell cancer therapies, giving Editas a potential income stream outside its core research focus. Development and regulatory milestones in those therapies could trigger payments, with royalties payable on future net product sales.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb's report can show whether it is still advancing cell therapies, the market context for program choices and milestones that could generate collaboration revenue for Editas.
Look for Bristol Myers Squibb's progress and investment in cell therapies. Continued work and resources would show that pharmaceutical demand for engineered T-cell treatments remains active, leaving a commercial basis for program choices or milestones that could pay Editas. A slowdown or pullback would make that revenue path harder to rely on, but would not by itself mean BMS has ended its Editas programs.
Vertex Pharmaceuticals Inc earningsVRTX
Vertex's report will show how CASGEVY sales are changing, which matters because some annual license fees it pays Editas can rise with sales.
Look at whether CASGEVY sales are growing. Growth can increase some annual license fees under the agreement, but Editas has assigned certain future payments to DRI and must also pay amounts owed to Broad and Harvard. Rising sales would point to stronger demand for the treatment and could lift the license income Editas retains; stagnant sales would weaken the case for sales-linked fee increases.
Beam Therapeutics Inc. earningsBEAM
Beam Therapeutics' report will show progress in its inherited blood-disorder programs, an area where it competes with Editas for development and market opportunities.
Look for progress in Beam Therapeutics' inherited blood-disorder programs. Faster progress would make Beam a stronger competitor in an area it shares with Editas; delays or setbacks would ease that pressure. Beam also uses patents controlled by Editas under an agreement that requires royalties, so program progress does not prove how Editas's own candidates are doing or establish the royalty amount.
Intellia Therapeutics, Inc earningsNTLA
Intellia Therapeutics' late-stage in vivo editing trials will test progress with lipid-nanoparticle delivery, offering a clinical reference for Editas's work on medicines that edit genes inside the body.
Look at results from Intellia Therapeutics' lonvo-z and nex-z trials. They use lipid nanoparticles to deliver treatment inside the body, but target different diseases from Editas's programs. Results supporting safety and effectiveness in people would add clinical evidence for this delivery approach; poor results would raise concerns about it, but would not show that Editas's candidates will have the same outcomes.
Editas Medicine, Inc. earningsThis company
Editas Medicine has no product-sales revenue, so this report shows whether collaboration income is keeping pace with the spending that drains its cash.
Read collaboration revenue beside cash used in operating activities: BMS option-package deliveries or milestone payments and Vertex license fees can make revenue timing uneven, and revenue recognized is not necessarily cash collected that quarter. Steady revenue with lower cash use would show collaboration income helping the company fund operations for longer. A revenue bump driven by a one-off milestone alongside heavy cash use would not establish a steady funding source; weak collaboration revenue with heavy cash use would make new financing more pressing.
Scribe Therapeutics Inc. earningsSCTX
Scribe Therapeutics Inc.'s report will show progress in its in vivo programs for cardiovascular risk, an area adjacent to Editas's priority program, EDIT-401.
Look for progress in Scribe Therapeutics Inc.'s programs targeting LDL cholesterol, Lp(a) and triglycerides. Faster progress would make Scribe a more active competitor in in vivo editing for cardiovascular risk and provide a development reference; stalled programs would mean less competitive pressure for Editas's EDIT-401, but would not prove that candidate works. Scribe currently receives collaboration payments rather than product-sales revenue, so program progress does not mean it has an established product market.
